A detailed history of Sg Americas Securities, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 26,149 shares of ZNTL stock, worth $90,998. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,149
Previous 14,152 84.77%
Holding current value
$90,998
Previous $58,000 65.52%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$2.9 - $4.57 $34,791 - $54,826
11,997 Added 84.77%
26,149 $96,000
Q2 2024

Jul 12, 2024

BUY
$4.09 - $16.13 $57,881 - $228,271
14,152 New
14,152 $58,000
Q4 2023

Jan 12, 2024

BUY
$9.84 - $20.13 $61,519 - $125,852
6,252 Added 4.27%
152,747 $2.31 Million
Q3 2023

Oct 13, 2023

BUY
$19.63 - $28.29 $1.43 Million - $2.06 Million
72,861 Added 98.95%
146,495 $2.94 Million
Q2 2023

Jul 10, 2023

BUY
$17.41 - $30.05 $1.28 Million - $2.21 Million
73,634 New
73,634 $2.08 Million
Q2 2022

Jul 29, 2022

BUY
$17.91 - $52.25 $341,221 - $995,467
19,052 Added 193.74%
28,886 $812,000
Q1 2022

Apr 29, 2022

SELL
$41.58 - $80.89 $401,247 - $780,588
-9,650 Reduced 49.53%
9,834 $454,000
Q4 2021

Feb 07, 2022

BUY
$66.92 - $84.79 $51,729 - $65,542
773 Added 4.13%
19,484 $1.64 Million
Q3 2021

Nov 01, 2021

BUY
$46.83 - $73.5 $344,013 - $539,931
7,346 Added 64.64%
18,711 $1.25 Million
Q2 2021

Aug 12, 2021

SELL
$37.41 - $62.25 $148,368 - $246,883
-3,966 Reduced 25.87%
11,365 $605,000
Q1 2021

May 13, 2021

BUY
$35.69 - $52.72 $265,141 - $391,656
7,429 Added 94.01%
15,331 $665,000
Q4 2020

Feb 04, 2021

SELL
$31.71 - $57.97 $1.38 Million - $2.52 Million
-43,520 Reduced 84.63%
7,902 $410,000
Q3 2020

Nov 09, 2020

BUY
$27.03 - $47.97 $1.24 Million - $2.2 Million
45,825 Added 818.74%
51,422 $1.68 Million
Q2 2020

Jul 20, 2020

BUY
$23.2 - $54.8 $129,850 - $306,715
5,597 New
5,597 $269,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $198M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.